Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity

被引:6
|
作者
Bermudo, Guadalupe [1 ]
Suarez-Cuartin, Guillermo [1 ]
Rivera-Ortega, Pilar [1 ,2 ]
Rodriguez-Portal, Jose Antonio [3 ]
Sauleda, Jaume [4 ]
Nunez, Belen [4 ]
Castillo, Diego [5 ]
Aburto, Myriam [6 ]
Portillo, Karina [7 ]
Balcells, Eva [8 ,9 ,10 ]
Badenes-Bonet, Diana [8 ,9 ,10 ]
Valenzuela, Claudia [11 ]
Fernandez-Fabrellas, Estrella [12 ]
Gonzalez-Budino, Teresa [13 ]
Cano, Esteban [14 ]
Acosta, Orlando [15 ]
Leiro-Fernandez, Virginia [16 ]
Romero, Ana [17 ]
Planas-Cerezales, Lurdes [1 ,18 ]
Villar, Ana [19 ]
Moreno, Amalia [20 ]
Laporta, Rosalia [21 ]
Vicens-Zygmunt, Vanesa [1 ]
Shull, Jessica [1 ]
Franquet, Tomas [5 ]
Luburich, Patricio [22 ]
Molina-Molina, Maria [1 ,10 ]
机构
[1] Univ Barcelona, Univ Hosp Bellvitge, IDIBELL, ILD Unit,Resp Dept, Barcelona, Spain
[2] Manchester Univ NHS Fdn Trust, Wythenshawe Hosp, Resp Dept, ILD Unit, Manchester, Lancs, England
[3] Univ Hosp Virgen del Rocio, Resp Dept, Seville, Spain
[4] Univ Hosp Son Espases, Resp Dept, Mallorca, Spain
[5] Univ Hosp Santa Creu & St Pau, Resp Dept, Barcelona, Spain
[6] Hosp Galdakao, Resp Dept, Bizkaia, Spain
[7] Univ Hosp Germans Trias & Pujol, Resp Dept, Badalona, Spain
[8] Univ Hosp del Mar, Resp Dept, Barcelona, Spain
[9] Pompeu Fabra Univ UPF, Barcelona, Spain
[10] CIBER Enfermedades Resp CIBERES, Madrid, Spain
[11] Univ Hosp Princesa, Resp Dept, Madrid, Spain
[12] Univ Hosp Gen Valencia, Resp Dept, Valencia, Spain
[13] Univ Hosp Cent Asturias HUCA, Resp Dept, Oviedo, Spain
[14] Univ Hosp Lucus Agusti, Resp Dept, Lugo, Spain
[15] Univ Hosp Canarias, Resp Dept, Santa Cruz De Tenerife, Spain
[16] Univ Hosp Alvaro Cunqueiro, Resp Dept, Vigo, Spain
[17] Univ Hosp Virgen de las Nieves, Resp Dept, Granada, Spain
[18] Hosp Viladecans, Resp Dept, Barcelona, Spain
[19] Univ Hosp Vall dHebron, Resp Dept, Barcelona, Spain
[20] Univ Hosp Parc Tauli, Resp Dept, Sabadell, Spain
[21] Univ Hosp Puerta del Hierro, Resp Dept, Majadahonda, Spain
[22] Univ Hosp Bellvitge, ILD Unit, Radiol Dept, Barcelona, Spain
来源
ARCHIVOS DE BRONCONEUMOLOGIA | 2022年 / 58卷 / 02期
关键词
Diffuse interstitial lung disease; Idiopathic pulmonary fibrosis; Early diagnosis; Prognosis; Mortality; INTERSTITIAL LUNG ABNORMALITIES; EFFICACY; INDEX; RISK;
D O I
10.1016/j.arbres.2021.03.018
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Introduction: Idiopathic pulmonary fibrosis (IPF) is progressive and irreversible. Some discrepancies about IPF staging exists, especially in mild phases. Forced vital capacity (FVC) higher than 80% has been considered early or mild IPF even for the design of clinical trials. Methods: Spanish multicentre, observational, retrospective study of IPF patients diagnosed between 2012 and 2016, based on the ATS/ERS criteria, which presented FVC greater or equal 80% at diagnosis. Clinical and demographic characteristics, lung function, radiological pattern, treatment, and follow-up were analyzed. Results: 225 IPF patients were included, 72.9% were men. The mean age was 69.5 years. The predominant high-resolution computed tomography (HRCT) pattern was consistent usual interstitial pneumonia (UIP) (51.6%). 84.7% of patients presented respiratory symptoms (exertional dyspnea and/or cough) and 33.33% showed oxygen desaturation below 90% in the 6 min walking test (6MWT). Anti-fibrotic treatment was initiated at diagnosis in 55.11% of patients. Median FVC was 89.6% (IQR 17) and 58.7% of patients had a decrease of diffusion lung capacity for carbon monoxide (DLCO) below 60% of theoretical value; most of them presented functional progression (61.4%) and higher mortality at 3 years (20.45%). A statistically significant correlation with the 3-years mortality was observed between DLCO <60% and consistent UIP radiological pattern. Conclusions: Patients with preserved FVC but presenting UIP radiological pattern and moderate-severe DLCO decrease at diagnosis associate an increased risk of progression, death or lung transplantation. Therefore, in these cases, preserved FVC would not be representative of early or mild IPF. (C) 2021 SEPAR. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:135 / 141
页数:7
相关论文
共 50 条
  • [41] Predictors of Stability/Improvement of Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis After One Year of Treatment With Nintedanib
    Mondoni, Michele
    Varone, Francesco
    Alfano, Fausta
    Muscato, Giuseppe
    Conti, Caterina
    Saderi, Laura
    Iovene, Bruno
    Di Marco, Fabiano
    Vancheri, Carlo
    Richeldi, Luca
    Centanni, Stefano
    Sotgiu, Giovanni
    ARCHIVOS DE BRONCONEUMOLOGIA, 2023, 59 (07): : 464 - 466
  • [42] First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
    Wim A. Wuyts
    Martin Kolb
    Susanne Stowasser
    Wibke Stansen
    John T. Huggins
    Ganesh Raghu
    Lung, 2016, 194 : 739 - 743
  • [43] Effect Of Nintedanib On Decline In Forced Vital Capacity (FVC) Over Time In The Inpulsis® Trials In Patients With Idiopathic Pulmonary Fibrosis
    Maher, T. M.
    Flaherty, K. R.
    Azuma, A.
    Cottin, V.
    Stansen, W.
    Quaresma, M.
    Wells, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [44] Relative Versus Absolute Decline in Forced Vital Capacity in Progressive Pulmonary Fibrosis
    Castro, Horacio Matias
    Furcada, Joaquin Maritano
    Enghelmayer, Juan Ignacio
    ARCHIVOS DE BRONCONEUMOLOGIA, 2022, 58 (12): : 843 - 844
  • [45] Biomarkers Replacing Forced Vital Capacity Testing in Idiopathic Pulmonary Fibrosis: The Views of Physicians in the US Compared to the EU5
    Roche, K.
    Moll, J.
    Phillip, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [46] Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis
    Biondini, Davide
    Balestro, Elisabetta
    Lacedonia, Donato
    Cerri, Stefania
    Milaneschi, Rosanna
    Luppi, Fabrizio
    Cocconcelli, Elisabetta
    Bazzan, Erica
    Clini, Enrico
    Barbaro, Maria Pia Foschino
    Gregori, Dario
    Cosio, Manuel G.
    Saetta, Marina
    Spagnolo, Paolo
    SCIENTIFIC REPORTS, 2018, 8
  • [47] Validation of A 25-Gene Blood Transcriptomic Signature Predictive of Forced Vital Capacity Decline in Patients With Idiopathic Pulmonary Fibrosis
    Bonham, C.
    Neely, M. L.
    Huang, Y.
    Ma, S.
    Kim, J. S.
    Oldham, J. M.
    Becker, K.
    Soellner, J.
    Todd, J. L.
    Noth, I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [48] Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?
    Karishma Hosein
    Jamie Le
    Marco Mura
    Lung, 2017, 195 : 101 - 105
  • [49] Stratification of long-term outcome in stable idiopathic pulmonary fibrosis by combining longitudinal computed tomography and forced vital capacity
    Sverzellati, Nicola
    Silva, Mario
    Seletti, Valeria
    Galeone, Carlotta
    Palmucci, Stefano
    Piciucchi, Sara
    Vancheri, Carlo
    Poletti, Venerino
    Tomassetti, Sara
    Karwoski, Ronald
    Bartholmai, Brian J.
    EUROPEAN RADIOLOGY, 2020, 30 (05) : 2669 - 2679
  • [50] A NEW METHOD TO EVALUATE THE CLINICAL EFFICACY OF PIRFENIDONE FOR PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS BY USING PERSONAL FORCED VITAL CAPACITY CHANGE
    Yamauchi, Hiroyoshi
    Bando, Masashi
    Ogura, Takashi
    Suda, Takafumi
    Taniguchi, Hiroyuki
    Mukae, Hiroshi
    Kishi, Kazuma
    Sugiyama, Yukihiko
    RESPIROLOGY, 2014, 19 : 151 - 151